More than five years after providing seed funding for Abexxa Biologics Inc, Boehringer Ingelheim GmbHhas decided to acquire the US-based oncology start-up which is developing what the German group hopes will be "the next generation of precision medicines designed to revolutionize cancer treatments."
Boehringer Buys Abexxa To Boost Cancer Pipeline
Provided Initial Funding For Start-Up In 2016
The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.
More from Deals
More from Business
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.